VIM and metabolic dysfunction-associated steatotic liver disease: In non-alcoholic fatty liver disease (NAFLD), miR-122 targets HIF-1α, vimentin, and mitogen-activated protein kinase kinase kinase 3, which regulate steatosis [53].